SCHEMBL3413420

SCHEMBL3413420

CC(O)(c1ccc2nccn2c1)c1cnc2ccc(Cl)nn12

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 11/20 0.43
DYRK2 Q92630 10/20 0.43
MET P08581 2/20 0.41
DYRK1B Q9Y463 9/20 0.38
CDK5 Q00535 7/20 0.38
CDK5R1 Q15078 7/20 0.38
DYRK3 O43781 7/20 0.38
CCNA2 P20248 6/20 0.38
CDK2 P24941 6/20 0.38
SSTR4 P31391 1/20 0.38
CCNT1 O60563 4/20 0.36
CDK9 P50750 4/20 0.36
TNF P01375 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MCHR1 Q99705 1/20 0.33
KEAP1 Q14145 1/20 0.33
MERTK Q12866 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3410453 0.74 MET (0.73) DYRK1ADYRK2METDYRK1BCDK5
SCHEMBL17789272 0.72 TNF (0.49) DYRK1ADYRK2DYRK1BCDK5CDK5R1
SCHEMBL19950935 0.72 SSTR4 (0.49) DYRK1ASSTR4MCHR1KEAP1MAOB
SCHEMBL1163693 0.72 MET (0.46) DYRK1ADYRK2METDYRK1BCDK5
SCHEMBL3409082 0.72 MET (0.46) DYRK1ADYRK2METDYRK1BCDK5
SCHEMBL22109400 0.70 ALDH1A1 (0.56) DYRK1ADYRK2METDYRK1BCDK5
SCHEMBL27904850 0.70 MCHR1 (0.48) DYRK1ASSTR4MCHR1KEAP1MAOB
SCHEMBL3412216 0.69 ADORA2A (0.48) DYRK1ADYRK2DYRK1BCDK5CDK5R1
SCHEMBL3411255 0.69 DYRK1A (0.40) DYRK1ADYRK2METDYRK1BCDK5
SCHEMBL3409818 0.69 DYRK1A (0.37) DYRK1ADYRK2METDYRK1BCDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822468-B2 3-Methyl-imidazo[1,2-b]pyridazine derivatives NOVARTIS AG (CH) 2014-09-02 US disclosed
EP-2265614-A1 IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE Novartis AG (CH) 2010-12-29 EP disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 US disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES MET, ERBB2, ALK DYRK1A 560/4885DYRK2 457/4885MET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.